ESCAGENETICS CORP
10QSB, 1999-01-12
COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH
Previous: ESCAGENETICS CORP, 10QSB, 1999-01-12
Next: ESCAGENETICS CORP, 10KSB, 1999-01-12



<PAGE>

                       SECURITIES AND EXCHANGE COMMISSION
                              WASHINGTON, DC 20549
                                   FORM 10-QSB

         Quarterly report under Section 13 or 15(d) of the Securities Exchange 
         Act of 1934

         For the quarterly period ended June 30, 1998

         Commission file number 1-9431

                            ESCAGENETICS CORPORATION
- -------------------------------------------------------------------------------
                 (Name of Small Business Issuer in Its Charter)

Delaware                                               94-3012230
- -------------------------------------------------------------------------------
(State or Other Jurisdiction of            (I.R.S. Employer Identification No.)
Incorporation or Organization)

Suite 605, 1075 Bellevue Way NE, Bellevue, WA                   98004
- -------------------------------------------------------------------------------
(Address of Principal Executive Offices)                      (Zip Code)

(206) 901-3595
- -------------------------------------------------------------------------------
(Issuer's Telephone Number, Including Area Code)

Check whether the issuer: (1) filed all reports required to be filed by Section
13 or 15(d) of the Exchange Act during the past 12 months (or for such shorter
period that the registrant was required to file such reports), and (2) has been
subject to such filing requirements for past 90 days.

Yes  X   No
            ----

Check whether the issuer has filed all documents and reports required to be
filed by Section 12, 13, or 15(d) of the Exchange Act after the distribution of
securities under a plan confirmed by a court.
Yes  X    No
             ----

The number of shares of the issuer's common stock outstanding as of December 15,
1998 was 73,402,516 shares, par value $0.0001 per share.


                                        
<PAGE>

                                     PART 1

ITEM 1 - Financial Statements

                      ESCAGENETICS CORPORATION AND SUBSIDIARIES

                           CONSOLIDATED BALANCE SHEET

                                   (Unaudited)
- -------------------------------------------------------------------------------

<TABLE>
<CAPTION>

                                                                                June 30,
                                                                                  1998
                                                                              --------------
                                      ASSETS
<S>                                                                           <C>
Current assets:
    Cash                                                                        $     1,000
                                                                              --------------

          Total assets                                                          $     1,000
                                                                              --------------
                                                                              --------------



                  LIABILITIES AND SHAREHOLDERS' EQUITY (DEFICIENCY)

Current liabilities:
    Accounts payable                                                            $     2,000
    Due to GFL Ultra Fund, Ltd.                                                      54,000
                                                                              --------------

       Total liabilities                                                             56,000
                                                                              --------------

Shareholders' equity (deficiency):
    Preferred stock; $0.01 par value; 1,000,000 shares
      authorized; none issued or outstanding
    Common stock; $0.0001 par value; 101,000,000 shares
      authorized; 73,402,516 shares issued and outstanding                            7,000
    Additional paid-in capital                                                      134,000
    Accumulated deficit                                                            (196,000)
                                                                              --------------

       Total shareholders' equity (deficiency)                                      (55,000)
                                                                              --------------

          Total liabilities and shareholders' equity (deficiency)               $     1,000
                                                                              --------------
                                                                              --------------
</TABLE>


                        SEE NOTE TO FINANCIAL STATEMENTS

                                        2
<PAGE>

                    ESCAGENETICS CORPORATION AND SUBSIDIARIES

                      CONSOLIDATED STATEMENTS OF OPERATIONS

                                   (Unaudited)
- -------------------------------------------------------------------------------

<TABLE>
<CAPTION>
                                                       Three months ended June 30,                  Nine months ended June 30,
                                                   ----------------------------------          ----------------------------------
                                                        1998                 1997                  1998                 1997
                                                   ------------          ------------          ------------          ------------
<S>                                                <C>                   <C>                   <C>                   <C>
Revenues:
    Miscellaneous                                   $        0            $        0            $        0            $    3,000
                                                   ------------          ------------          ------------          ------------

Operating expenses:
    Accounting and legal                                                       9,000                 5,000               125,000
    General and administrative                           2,000                 5,000                 8,000                35,000
                                                   ------------          ------------          ------------          ------------

       Total expenses                                    2,000                14,000                13,000               160,000
                                                   ------------          ------------          ------------          ------------

Net loss                                                (2,000)              (14,000)              (13,000)             (157,000)

Accumulated deficit, beginning of period              (194,000)             (158,000)             (183,000)              (15,000)
                                                   ------------          ------------          ------------          ------------

Accumulated deficit, end of period                  $ (196,000)           $ (172,000)           $ (196,000)           $ (172,000)
                                                   ------------          ------------          ------------          ------------
                                                   ------------          ------------          ------------          ------------


Net loss per share                                  $    (0.00)           $    (0.00)           $    (0.00)           $    (0.00)
                                                   ------------          ------------          ------------          ------------
                                                   ------------          ------------          ------------          ------------

Weighted average common shares outstanding          73,402,516            73,402,516            73,402,516           73,402,5166
                                                   ------------          ------------          ------------          ------------
                                                   ------------          ------------          ------------          ------------
</TABLE>

                           SEE NOTE TO FINANCIAL STATEMENTS

                                        3
<PAGE>

                    ESCAGENETICS CORPORATION AND SUBSIDIARIES

                      CONSOLIDATED STATEMENTS OF CASH FLOWS

                                   (Unaudited)
- -------------------------------------------------------------------------------

<TABLE>
<CAPTION>
                                                                   Nine months ended June 30,
                                                               ---------------------------------
                                                                   1998                  1997
                                                               -----------           -----------
<S>                                                            <C>                   <C>
Cash flows from operating activities:
    Net loss                                                    $ (13,000)            $(157,000)
    Adjustments to reconcile net loss to net cash flows
      used in operating activities:
       Changes in operating assets and liabilities:
          Prepaid expenses                                                               (1,000)
          Accounts payable                                         (1,000)                4,000
          Amounts due to pre-petition creditors                                        (216,000)
                                                               -----------           -----------

              Net cash used in operating activities               (14,000)             (370,000)
                                                               -----------           -----------

Cash flows from investing activities:
    Additional investment in Potato Products
      International, Ltd. prior to sale                                                 (27,000)
    Proceeds from sale of Potato Products
      International, Ltd.                                                               175,000
                                                               -----------           -----------

              Net cash provided by investing activities                 0               148,000
                                                               -----------           -----------

Cash flows from financing activities:
    Advances from GFL Ultra Fund, Ltd.                             15,000               137,000
    Repayments to GFL Ultra Fund, Ltd.                                                 (135,000)
                                                               -----------           -----------

              Net cash provided by financing activities            15,000                 2,000
                                                               -----------           -----------

Net decrease in cash                                                1,000              (220,000)

Cash at beginning of period                                             0               224,000
                                                               -----------           -----------

Cash at end of period                                           $   1,000             $   4,000
                                                               -----------           -----------
                                                               -----------           -----------
</TABLE>


                          SEE NOTE TO FINANCIAL STATEMENTS

                                        4

<PAGE>

                    ESCAGENETICS CORPORATION AND SUBSIDIARIES

                   NOTE TO CONSOLIDATED FINANCIAL STATEMENTS

       FOR THE THREE AND NINE MONTH PERIODS ENDED JUNE 30, 1998 AND 1997

- --------------------------------------------------------------------------------

1.   Unaudited information

     The consolidated financial statements for the three and nine month periods
     ended June 30, 1998 and 1997 are unaudited and reflect all adjustments
     which are, in the opinion of management, necessary for the fair
     presentation of the financial position and operating results for the
     periods presented. Certain footnote disclosures normally included with
     financial statements prepared in accordance with generally accepted
     accounting principles have been omitted from these financial statements.
     Accordingly, these unaudited consolidated financial statements should be
     read in conjunction with the September 30, 1997 audited consolidated
     financial statements and notes thereto included in the Company's annual
     report on Form 10-KSB for the year ended September 30, 1997.



                                        5


<PAGE>

ITEM 2 - Management's Discussion and Analysis of Financial Condition and
      Results of Operations

Effective as of August 22, 1996 the Company was reorganized pursuant to a plan
of reorganization that was confirmed by the US Bankruptcy Court. Since the
reorganization date, the Company has adopted a September 30 fiscal year.

The Company has had no revenues from operations since the reorganization date.
The Company does not plan to continue the business activities that it previously
conducted. It plans to pursue a business combination or other strategic
transaction. No candidate for such a transaction has been identified. The
Company believes its status as a public company may be attractive to a private
company wishing to avoid an initial public offering but there is no guarantee
that a business combination or other strategic transaction will be consummated.

The Company expects to fund its expenses during fiscal 1998 with advances from
its majority shareholder, GFL Ultra Fund, Ltd. ("Ultra"). These advances are
expected to total approximately $15,000 during fiscal 1998. The Company expects
Ultra to continue to fund its expenses until a business combination or other
strategic transaction is consummated. There is no guarantee that the Company is
a viable party for a business combination or other strategic transaction. If a
business combination or other strategic transaction is not consummated in a
timeframe suitable to Ultra or cannot be consummated due to excessive cost or
for any other reason, Ultra will cease to advance funds to the Company.

The Company has no employees and no fixed assets. The Company does not
anticipate hiring any employees or purchasing any assets until such time as a
business combination or other strategic transaction is consummated or is
imminent.



                                    PART II


ITEM 1 - Legal Proceedings

None.


ITEM 2 - Changes in Securities and Use of Proceeds

None.


ITEM 3 - Defaults Upon Senior Securities

None.


ITEM 4 - Submission of Matters to a Vote of Security Holders

None.


                                        6
<PAGE>

ITEM 5 - Other Items

None.


ITEM 6 - Exhibits and Reports on Form 8-K

(a)  Exhibits

27.1   Financial Data Schedule

(b)  Forms 8-K

No reports on Form 8-K were filed during the quarter ended June 30, 1998.

                                   SIGNATURES

In accordance with Section 13 or 15(d) of the Exchange Act, the registrant
caused this report to be signed on its behalf by the undersigned, thereunto duly
authorized.

ESCAGENETICS CORPORATION


By /s/ Michelle Kline
   -------------------------------
         Michelle Kline
         President and Treasurer
         (Principal Executive Officer and
         Principal Financial Officer)


Dated:  January 12, 1999
       ---------------------------



                                        7

<TABLE> <S> <C>

<PAGE>
<ARTICLE> 5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM UNAUDITED
CONSOLIDATED FINANCIAL STATEMENTS FILED WITH THE COMPANY'S JUNE 30, 1998
QUARTERLY REPORT ON FORM 10-QSB AND IS QUALIFIED IN ITS ENTIRETY BY REFERENCE TO
SUCH FINANCIAL STATEMENTS.
</LEGEND>
<MULTIPLIER> 1
<CURRENCY> US $
       
<S>                             <C>
<PERIOD-TYPE>                   9-MOS
<FISCAL-YEAR-END>                          SEP-30-1997
<PERIOD-END>                               JUN-30-1998
<EXCHANGE-RATE>                                      1
<CASH>                                           1,000
<SECURITIES>                                         0
<RECEIVABLES>                                        0
<ALLOWANCES>                                         0
<INVENTORY>                                          0
<CURRENT-ASSETS>                                 1,000
<PP&E>                                               0
<DEPRECIATION>                                       0
<TOTAL-ASSETS>                                   1,000
<CURRENT-LIABILITIES>                           56,000
<BONDS>                                              0
                                0
                                          0
<COMMON>                                         7,000
<OTHER-SE>                                    (62,000)
<TOTAL-LIABILITY-AND-EQUITY>                     1,000
<SALES>                                              0
<TOTAL-REVENUES>                                     0
<CGS>                                                0
<TOTAL-COSTS>                                        0
<OTHER-EXPENSES>                                13,000
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                                   0
<INCOME-PRETAX>                               (13,000)
<INCOME-TAX>                                         0
<INCOME-CONTINUING>                           (13,000)
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                  (13,000)
<EPS-PRIMARY>                                        0
<EPS-DILUTED>                                        0
        

</TABLE>


© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission